Cagrilintide + Semaglutide
Dual-Mechanism Satiety Stack
Cagrilintide (long-acting amylin analogue) + Semaglutide (GLP-1 agonist) — two complementary satiety pathways combined for additive fat loss beyond either compound alone.
Starting From
$109.99
Sold By
Apollo Peptide Sciences
Suggested Protocol
Dose escalation: 0.25mg each component weekly for 4 weeks, escalating gradually. Target maintenance dose 1–2.4mg of each component weekly. SubQ injection once weekly. The slower escalation vs. semaglutide alone helps minimize GI side effects from dual receptor activation.
2
Satiety Pathways
GLP-1 + Amylin
Receptors
15.6%
Weight Loss
Two Completely Different Satiety Systems. One Injection. Why CagriSema Outperforms Either Alone.
The Cagrilintide + Semaglutide combination — the basis for the pharmaceutical compound CagriSema currently in Phase 3 trials — represents a sophisticated dual-pathway approach to appetite and weight regulation. While semaglutide operates through the GLP-1 receptor system, cagrilintide acts through an entirely separate mechanism: the amylin receptor pathway.
Cagrilintide is a long-acting analogue of amylin — a hormone co-secreted with insulin from pancreatic beta cells that signals satiety through the hindbrain. Amylin complements GLP-1's hypothalamic satiety signals with brainstem-level fullness signaling — creating satiety through two anatomically and mechanistically distinct pathways simultaneously. The combination is not merely additive: early clinical data from the CagriSema program suggests the two compounds produce synergistic satiety effects that exceed what either compound achieves alone.
The SCALE program demonstrated that CagriSema (2.4mg semaglutide + 2.4mg cagrilintide weekly) achieved up to 15.6% weight loss in 32 weeks — with ongoing Phase 3 trials suggesting outcomes potentially approaching tirzepatide. The dual-mechanism approach also appears to be particularly effective for individuals who have experienced plateau effects with semaglutide alone.
Apollo supplies this as a 5mg/5mg blended vial, providing both compounds in a single convenient formulation.
The Amylin Mechanism
What Cagrilintide Does That No GLP-1 Agonist Can Replicate — and Why That Matters
GLP-1 receptor agonists (semaglutide, tirzepatide) produce satiety through the hypothalamus — the brain's energy regulation center. Cagrilintide works through an entirely different anatomical pathway: the amylin receptor in the hindbrain area postrema, a region that receives direct gut-brain signals about meal size and fullness. Amylin is co-secreted with insulin after meals and signals "enough food" — a separate circuit from the GLP-1 "stop eating" signal. By activating both pathways simultaneously, CagriSema creates satiety that's reinforced at two independent brain regions: the combination is genuinely more powerful than either compound alone.
The Plateau Solution
Why People Who Stop Responding to Semaglutide Often Respond to CagriSema
Semaglutide tolerance — where appetite suppression diminishes after months of use — is a real phenomenon. The hypothalamic GLP-1 receptors down-regulate with sustained agonist exposure, reducing the appetite-suppressing effect over time. Cagrilintide's amylin pathway doesn't share this down-regulation pattern — it works through separate receptors that don't compete with or adapt to GLP-1 agonism. For researchers who've experienced a plateau on semaglutide, adding cagrilintide engages a fresh satiety circuit that the body hasn't habituated to, producing renewed appetite suppression and resumed fat loss momentum.
CagriSema vs. Tirzepatide
Two Different Approaches to Improving on Semaglutide — What Makes Each Unique
Tirzepatide improves on semaglutide by adding GIP receptor agonism — enhancing fat loss and insulin sensitivity through a complementary metabolic pathway. CagriSema improves on semaglutide by adding amylin-pathway satiety — a neurological complement rather than a metabolic one. They address different limitations. Tirzepatide is the superior choice for researchers primarily seeking maximum fat loss and metabolic improvement. CagriSema is uniquely valuable for researchers who have found semaglutide tolerable but insufficient, or who have experienced GI issues with tirzepatide's GIP component. The Phase 3 CagriSema data continues to emerge — but the mechanism alone makes it a compelling second-line alternative for serious weight management research.
Key Benefits
Dual satiety pathway activation: GLP-1 receptor + amylin receptor simultaneously
Synergistic appetite suppression beyond semaglutide monotherapy
Additive fat loss vs. either compound used alone
Pre-blended 5mg/5mg vial — single injection covers both compounds
Particularly effective for individuals who have plateaued on semaglutide
Slows gastric emptying via both amylin and GLP-1 mechanisms
Based on the CagriSema pharmaceutical program — Phase 3 clinical data pending
Weekly dosing protocol maintains semaglutide's convenient administration schedule
Full Protocol
Dose escalation: 0.25mg each component weekly for 4 weeks, escalating gradually. Target maintenance dose 1–2.4mg of each component weekly. SubQ injection once weekly. The slower escalation vs. semaglutide alone helps minimize GI side effects from dual receptor activation.
Best Stacked With
More in Weight Management
View All
Semaglutide
The compound behind Ozempic/Wegovy. GLP-1 receptor agonist producing significant appetite suppression, fat loss, and metabolic improvement with once-weekly dosing.
